ThirdLaw Molecular is a technology company.
ThirdLaw Molecular has raised $2.0M across 1 funding round.
ThirdLaw Molecular has raised $2.0M in total across 1 funding round.
ThirdLaw Molecular has raised $2.0M in total across 1 funding round.
ThirdLaw Molecular's investors include SmartGateVC, Roy Peterkofsky.
ThirdLaw Molecular, now rebranded as Ladder Bio, is a biotechnology company pioneering a novel therapeutic platform based on Spiroligomer™ molecules—synthetic, ladder-shaped peptide-like compounds designed for targeted drug discovery. These molecules combine the specificity and potency of biologics with the stability, oral availability, and cell permeability of small molecules, aiming to address disease targets traditionally considered "undruggable." Ladder Bio serves pharmaceutical partners and ultimately patients by developing new therapeutics, initially focusing on cancer and anti-inflammatory indications. The company has demonstrated growth momentum through the launch of a vast DNA-encoded library of 4.5 billion Spiroligomer macromolecules and securing $5.5 million in seed financing to advance product development[1][2][4].
Founded in 2020 by Dr. Christian Schafmeister, a Temple University chemistry professor and inventor of Spiroligomer technology, ThirdLaw Molecular emerged from academic research into synthetic alternatives to proteins. The idea originated from Schafmeister’s long-standing ambition to start a company and was catalyzed by interest from the U.S. Department of Defense in applying the technology for diagnostic and therapeutic uses. Early traction included partnerships with pharmaceutical companies evaluating their molecule libraries and attracting notable investors like Wayne Braccia. The company evolved from a university spinout to Ladder Bio in 2025, reflecting a sharpened focus on therapeutics and the appointment of industry veterans to its leadership and board[1][2][4].
Ladder Bio rides the trend of expanding drug modalities beyond traditional small molecules and biologics to address unmet medical needs. The timing is critical as the pharmaceutical industry increasingly seeks novel platforms to target complex diseases, including cancer and inflammatory disorders, with higher precision and fewer side effects. Advances in synthetic chemistry, DNA-encoded libraries, and computational design converge to enable Ladder Bio’s approach. By unlocking new chemical space and enabling oral, cell-permeable therapeutics, Ladder Bio influences the ecosystem by potentially transforming drug discovery paradigms and expanding the range of treatable targets[1][2][4].
Looking ahead, Ladder Bio is positioned to advance from platform validation to clinical-stage product development, leveraging its recent $5.5 million seed round and leadership enhancements. Trends such as personalized medicine, synthetic biology, and the pursuit of "undruggable" targets will shape its trajectory. As the company scales, its influence may grow by enabling new classes of medicines that combine the best attributes of biologics and small molecules, potentially reshaping therapeutic strategies across multiple disease areas. Ladder Bio’s evolution from ThirdLaw Molecular underscores its commitment to pioneering a revolutionary drug discovery platform with broad implications for healthcare innovation[2][4].
ThirdLaw Molecular has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in February 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2025 | $2.0M Seed | SmartGateVC, Roy Peterkofsky |